Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 4/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25359258 | 0.96 | KMT2A (0.54) | KMT2AHDAC1HDAC2CASP3TLR2 | |
| SCHEMBL31144370 | 0.96 | KMT2A (0.54) | KMT2AHDAC1HDAC2CASP3TLR2 | |
| SCHEMBL26008676 | 0.96 | KMT2A (0.54) | KMT2AHDAC1HDAC2CASP3TLR2 | |
| SCHEMBL25359262 | 0.96 | KMT2A (0.54) | KMT2AHDAC1HDAC2CASP3TLR2 | |
| SCHEMBL28510322 | 0.92 | KMT2A (0.51) | KMT2ACASP3TLR2MDM4TP53 | |
| SCHEMBL10173082 | 0.92 | KMT2A (0.51) | KMT2ACASP3TLR2MDM4TP53 | |
| SCHEMBL15280776 | 0.92 | KMT2A (0.51) | KMT2ACASP3TLR2MDM4TP53 | |
| SCHEMBL30471287 | 0.92 | KMT2A (0.51) | KMT2ACASP3TLR2MDM4TP53 | |
| SCHEMBL29398585 | 0.92 | KMT2A (0.51) | KMT2ACASP3TLR2MDM4TP53 | |
| SCHEMBL29401691 | 0.92 | KMT2A (0.51) | KMT2ACASP3TLR2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004290-A1 | Anti-Cancer Agents | THE UNIVERSITY OF QUEENSLAND (AU) | 2008-01-03 | — | — | US | disclosed |
| EP-1694640-A4 | ANTI-CANCER AGENTS | UNIV QUEENSLAND (AU) | 2007-01-10 | — | — | EP | disclosed |
| EP-1694640-A1 | ANTI-CANCER AGENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005051901-A1 | ANTI-CANCER AGENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004290-A1 | Anti-Cancer Agents | TP53, TOP2A, MCL1 | KMT2A 2124/4885HDAC1 90/4885HDAC2 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.